SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (1829)5/4/2005 4:41:06 PM
From: arnie h  Read Replies (1) | Respond to of 2173
 
Interesting technology but probably many 'moons' from any practical use. Also, it will probably lead to the same disadvantages of Insulin.
Settled on the $30 calls of '07. Perhaps by then, they'll be making progress on selling their 2 drugs as well as progress along the lines of a stand alone Exenatide product with fewer injections, even if not a stand alone at that time.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News